Cogstate CIO, Paul Maruff, recently presented data at #ADPD2024 showing carriers of APOE e4 can experience very early stage disruptions in acetylcholine neurotransmission. This research highlights the importance of amyloid levels as biomarkers for disease progression and opens the door for considering clinical trial study designs that look to ameliorate loss of cholinergic neurotransmission. “With the understanding of amyloid and how it influences both cognition and symptoms, there's been an opportunity to reconsider how acetylcholine neurotransmission is relevant to those relationships,” said Prof Maruff. “At Cogstate, we've been interested in trying to understand how design of studies would occur to test these hypotheses and in this presentation we outline a broader framework within which that might occur.” Watch the presentation summary 👉 https://lnkd.in/eJkFTtw2
Cogstate’s Post
More Relevant Posts
-
A new systems-level approach, published in JOR Spine, sheds light on the contribution of epigenetics to Marfan syndrome (MFS) and offers a plausible explanation for the complex phenotypes that are linked to reduced lifespan in untreated MFS patients. #ORSSMC https://buff.ly/4bCxDAs
-
-
Postdoctoral research fellow in The MGH/HST Martinos Center for Biomedical Imaging
Our recent work has been published in the journal "Pain"! We investigated whether the level of epigenetic enzyme (histone deacetylase) is different between chronic low back pain patients (naive to opioids) vs. age-sex-matched healthy volunteers. With our tremendous radiotracer [11C]Martinostat, we revealed that histone deacetylase levels were altered in the patient cohorts. I appreciate Dr. Hsiao-Ying (Monica) Wey, my boss, for allowing me to lead this project and for all the efforts from colleagues and collaborators. Please fine the detail here: https://lnkd.in/g_pT7-Vz
-
Vancomycin is occassionaly associated with acute kidney injury. Combining Vancomycin with imipenem-cilastatin shows promise of protection against kidney injury in translational rat models. https://ow.ly/y2Pz50S00cG Gwendolyn P. et al. #Vancomycin #Flucloxacillin #ImipenemCilastatin
-
-
Have you joined the Future of Health Revolution? If not then you're going to want catch up with this week's blog post! We're exploring genetic functional lab and dynamic blood chemistry testing. This isn't a simple health update; it's a full-scale revolution in understanding and optimizing well-being! Don't wonder if you're at the forefront—make sure you're part of this transformative movement. Read our blog now and stay ahead of pack! https://lnkd.in/gcEvUZcp #FunctionalMedicineRevolution #HealthOptimization #HealthInnovation #GeneticTesting #BloodChemistry #WellnessJourney #HealthInsights #RevolutionaryWellness #LeadingTheChange #StayInformed #HealthRevolutionaries
-
📜 Explore evidence-based guidelines by EFIC, EAN, and NeuPSIG on screening questionnaires and diagnostic tests for neuropathic pain (NeP). 💡 Read the full paper via the following link: https://lnkd.in/dtdYTBar #NeuropathicPain
-
-
Can you identify the symptoms of ISM? Take the Challenge Today | Mastering Mast Cell Mysteries: A Clinical Case Challenge in Recognizing and Managing Indolent Systemic Mastocytosis | 0.25 CME/CE | #MedEd #cme #medicalchallenge #ISM | https://bit.ly/3Wz1zce
-
-
Can you identify the symptoms of ISM? Take the Challenge Today | Mastering Mast Cell Mysteries: A Clinical Case Challenge in Recognizing and Managing Indolent Systemic Mastocytosis | 0.25 CME/CE | #MedEd #cme #medicalchallenge #ISM | https://bit.ly/3Wz1zce
-
-
📜 Explore evidence-based guidelines by EFIC, EAN, and NeuPSIG on screening questionnaires and diagnostic tests for neuropathic pain (NeP). 💡 Read the full paper via the following link: https://brnw.ch/21wEwFa #NeuropathicPain
-
-
In a recent case report study of a 32-year-old man with typical clinical features of #FriedreichAtaxia, parental sample testing identified a novel intragenic deletion. #NeurologyNews #MovementDisorders #DiseaseSpotlight View: https://lnkd.in/e8bae7DE
-
-
Research Update: “Here, we report a case of a 77-year-old female, living with idiopathic Parkinson's Disease for over 17 years. The patient received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs). A total of 26 infusion treatments of HB-adMSCs were administered over the course of ~2 years that resulted in marked improvements in her typical Parkinsonian symptoms, as demonstrated by the decreases in her UPDRS (Unified Parkinson's Disease Rating Scale) scores. Changes in clinical scores mirrored concurrent changes in regional brain metabolism as quantified by FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography), compared to baseline.” What does all of this mean for her quality of life? Read more >>> https://lnkd.in/gKZpS68Z #parkinsons #pd #celltherapy #research #scienceinservice #published #thursdaythoughts
-
